DURHAM, N.C., June 16, 2022 /PRNewswire/ -- BioAgilytix Labs, LLC ("BioAgilytix"), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, today announces the appointment, effective immediately, of Euan Menzies as Chairman and CEO. Jim Datin is retiring from his executive management role but will continue to serve as a non-executive member of the Board of Directors.
Euan Menzies joins BioAgilytix with significant experience and a proven background as CEO and Chairman of several software and business services companies. Most notably, he was Chairman and CEO of Bioclinica until its successful merger with ERT (now Clario) in April 2021. Previous roles include over ten years as CEO at Vertafore, a highly successful financial services software company. Prior to that he was a senior executive with The Thomson Corporation (now Thomson Reuters).
Jim Datin served as CEO since 2013, during which time he led the company through a period of exponential growth while maintaining the industry's highest customer satisfaction and employee retention rankings.
"It has been an incredible experience to serve as CEO during this period of growth and transformation," said Datin. "We have accomplished so much together as a team, and I look forward to continuing to support the company in my role as a non-executive board member."
"I am thrilled to assume my new role at BioAgilytix and I look forward to working with my colleagues across our key locations in the US, Europe and Australia," said Menzies. "By focusing on providing outstanding quality and timeliness for our clients, we will continue to grow at an accelerated pace."
In recent months, BioAgilytix also appointed two new scientific officers and top healthcare executive David King joined its board of directors.
About BioAgilytix
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina'sResearch Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix's team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.
Photo - https://mma.prnewswire.com/media/1841454/BioAgilytix_Euen_Menzies.jpg
